News Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ Continue Reading Previous Aleafia Health to Announce Fiscal Year 2022 Fifth Quarter and Year End Results – UpdateNext Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update Related Stories News Best VPN for Android 2025: NordVPN Voted Best of VPNs for Android News WiFi Profits Under Review: How to Get Dumb Money with Wireless News insightsoftware Launches Spreadsheet Server Integration with Infor M3 Cloud, Accelerating Self-Service Reporting in Excel News Hyper Bit Joins American Blockchain & Cryptocurrency Association News Syntheia Signs Non-Binding LOI for Call Center Acquisition News Metaguest.AI Announces Resignation of Director
